# Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer

> **NCT04705649** · NA · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 42 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **OTHER:** Treatment de-escalation

## Key facts

- **NCT ID:** NCT04705649
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2023-06-22
- **Final completion:** 2023-06-22
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705649, "Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04705649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*